Hayat Pharmaceutical Industries Co. Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JO4121011012
JOD
3.15
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Hayat Pharmaceutical Industries Co. Ltd. stock-summary
stock-summary
Hayat Pharmaceutical Industries Co. Ltd.
Pharmaceuticals & Biotechnology
Hayat Pharmaceutical Industries Company PSC is a Jordan-based company engaged in the pharmaceutical sector. The Company specializes in the manufacture of different forms of human pharmaceuticals, veterinary medicines, medical plasters, medical gauze and medical braces, in addition to the production of skin care and beauty supplies and surgical suture. The Company’s manufacturing facility is spread over an approximately 8,000 square meter area on the outskirts of the capital city Amman. The Company’s production areas are divided into the following: Solid production area, which covers tablets, capsules, dry suspension, suppositories, syrups and solutions, cream and ointments, and Semi-solid and Liquid production area, which includes creams, ointments, gels and emulsions, suppositories line, syrups line and shampoo line. The Company’s products include Anti-microbials, Gynecological, Dermatological, Gastrointestinal, Antihypertensives and Vasoactive, Neurological, and Respiratory products.
Company Coordinates stock-summary
Company Details
Nile St. Al-Rajeeb,, P.O.Box 1564 AMMAN None : 11118
stock-summary
Tel: 962 6 4162607
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Maher Al Kurdi
Chairman of the Board and General Manager
Dr. Fouad Bijali
Vice Chairman of the Board, representing Comsal for Trade & Investment Co
Dr. Muwafaq Al Bijari
Member of the Board
Dr. Raghda Al Kurdi
Member of the Board
Izz Alddin Katkhuda
Member of the Board
Ahmad Majdalawiya
Member of the Board, representing Elixir Investment Company
Ammar Khouldoon Malhas
Member of the Board
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
3 Million
(Quarterly Results - Jun 2025)
Net Profit:
0 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

JOD Million (Small Cap)

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.15

stock-summary
Return on Equity

10.94%

stock-summary
Price to Book

0.00